Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

NCT04277637 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

437

Enrollment

INDUSTRY

Sponsor class

Conditions

Mature B-Cell Malignancies

Interventions

DRUG: Sonrotoclax
DRUG: Zanubrutinib
DRUG: Obinutuzumab

Sponsor

BeOne Medicines